Estudio del macrozoobentos durante durante el crucero de evaluación de recursos demersales BIC José Olaya Balandra 9806-07 de Puerto Pizarro a Huarmey

Estudia las muestras obtenidas en cuatro lances ubicados en el sublitoral peruano de fondo blando al norte de los 8°S frente a Puerto Pizarro, Paita, Sechura y Pimentel durante los meses de junio y julio de 1998. Los resultados obtenidos reflejan una relación directa entre las comunidades macrozoobentónicas y el recurso demersal. Se observa que las distribuciones de densidades, biomasas y diversidad son mayores en la subáreas al norte de los 6°S, teniendo como grupo más representativo a los anélidos Polychaeta.

Comportamiento de la red de arrastre de fondo tipo 450/120 empleada en el estudio de recursos demersales a inicios del invierno 1998. BIC José Olaya Balandra 9806-07 de Puerto Pizarro a Huarmey

Se determinaron correlaciones entre diferentes parámetros de funcionamiento de la red de arrastre empleadas para las calas de comprobación. Abertura vertical con Abertura horizontal, profundidad con longitud de cable, abertura vertical y abertura horizontal versus velocidad de arrastre, analizándose un total de 72 lances de comprobación. Los datos de comportamiento de la red como la abertura horizontal y abertura vertical de la boca de la red, profundidad de la red y distancia entre la relinga inferior al fondo, etc. se obtuvo en forma directa por medio del sistema SCANMAR RX 400, los arrastres tuvieron una duración promedio de 13,58 minutos con una velocidad de arrastre promedio de 3,8 nudos. Se aplicó el modelo de regresión lineal para la correlación entre los valores de: (a) abertura vertical y abertura horizontal, (b) longitud del cable de arrastre principal con la profundidad de arrastre, (c) abertura horizontal-vertical y la velocidad de arrastre.

Respuesta selectiva de la red de arrastre del fondo tipo 450/120 empleada en el estudio de recursos demersales a inicios del invierno 1998. Crucero BIC José Olaya Balandra 9806-07 de puerto Pizarro a Huarmey

Estudia la respuesta selectiva de la red de arrastre de fondo tipo 450/120, utilizada en la toma de muestras durante el Crucero BIC José Olaya Balandra 9806-07 empleando el método de copo cubierto, con un tamaño de malla de 90 mm. (Polipropileno PP). Se obtuvieron las ojivas de selección mediante el método de la curva logística, para la zona de toda la extensión que abarcó el crucero desde las subáreas A, B, C, D, E, F, G y H (3°30 'S - 11°00 'S), presentando una L50%=23,68 cm. y curvas de selectividad parciales de las subáreas A, B, C y D, E, F, G y H con una L50%=25,45 cm. y L50%=23,68 cm. respectivamente. Se encontró un factor de selección general de (FS)=2,63. Los resultados fueron mayores que en el experimento modelo de selectividad con red de arrastre de fondo, realizado en invierno 1997.

Informe del crucero de evaluación acústica BIC/SNP-1, BIC/Humboldt 8805-07 y diagnóstico de la situación de los recursos pelágicos a julio 1988

Da a conocer los resultados del crucero de prospección acústico-pesquero y evaluación de los recursos pelágicos, efectuado por los buques de investigación científica del 11 de mayo al 13 de julio de 1988, en el área comprendida entre la frontera sur (Chile) a la frontera norte (Ecuador).

Iowa Supreme Court, Marriage Case, docket No. 07-1449.

In a unanimous decision, the Iowa Supreme Court today held that the Iowa statute limiting civil marriage to a union between a man and a woman violates the equal protection clause of the Iowa Constitution. The decision strikes the language from Iowa Code section 595.2 limiting civil marriage to a man and a woman. It further directs that the remaining statutory language be interpreted and applied in a manner allowing gay and lesbian people full access to the institution of civil marriage.

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.

The O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is a predictive parameter for the response of malignant gliomas to alkylating agents such as temozolomide. First clinical trials with temozolomide plus bevacizumab therapy in metastatic melanoma patients are ongoing, although the predictive value of the MGMT promoter methylation status in this setting remains unclear. We assessed MGMT promoter methylation in formalin-fixed, primary tumor tissue of metastatic melanoma patients treated with first-line temozolomide and bevacizumab from the trial SAKK 50/07 by methylation-specific polymerase chain reaction. In addition, the MGMT expression levels were also analyzed by MGMT immunohistochemistry. Eleven of 42 primary melanomas (26%) revealed a methylated MGMT promoter. Promoter methylation was significantly associated with response rates CR + PR versus SD + PD according to RECIST (response evaluation criteria in solid tumors) (p<0.05) with a trend to prolonged median progression-free survival (8.1 versus 3.4 months, p>0.05). Immunohistochemically different protein expression patterns with heterogeneous and homogeneous nuclear MGMT expression were identified. Negative MGMT expression levels were associated with overall disease stabilization CR+PR+SD versus PD (p=0.05). There was only a poor correlation between MGMT methylation and lack of MGMT expression. A significant proportion of melanomas have a methylated MGMT promoter. The MGMT promoter methylation status may be a promising predictive marker for temozolomide therapy in metastatic melanoma patients. Larger sample sizes may help to validate significant differences in survival type endpoints.

Aspectos oceanográficos en el invierno 2008: Crucero pelágico BIC Humboldt 0806-07

El Crucero BIC Humboldt 0806-07 se desarrolló del 3 de junio al 17 de julio 2008 en todo el mar peruano, como una evaluación hidroacústica del jurel (Trachurus murphyi) y la caballa (Scomber japonicus). Se registraron condiciones atípicas y grandes áreas de mezcla para la época. Las observaciones más importantes fueron: (1) las temperaturas fluctuaron entre 15,9 y 24,8 °C originando anomalías térmicas superficiales hasta de 2,6 °C en la zona norte, y anomalías próximas a lo normal en la zona sur; (2) la salinidad entre los 5 y 10°S mostró rezagos de la proyección de aguas ecuatoriales y tropicales durante el verano; (3) en la zona central se observó una marcada advección hacia la costa de aguas subtropicales superficiales entre Huarmey y Cerro Azul, formando una barrera para las aguas frías procedentes del sur; (4) estas aguas, al no proyectarse hacia el norte, giraron hacia el oeste originando mezclas y desplazamiento longitudinal de isotermas; (5) el afloramiento en general se mostró débil y restringido a la zona costera, principalmente entre San Juan y Ocoña; (6) en el nivel subsuperficial se registró una proyección de la Extensión Sur de la Corriente de Cromwell hasta el Callao; (7) en el sur, frente a Ocoña, se observó la presencia de Aguas Templadas de la Subantártica entre 25-70 mn y en la sección La Concordia fuera de las 250 mn.

5-Azacytidine to Treat Acute Myeloid Leukemia In Elderly or Frail Patients: A Phase II Study (SAKK 30/07).

Background: Acute Myeloid Leukemia (AML) in the elderly is notoriously difficult to treat and has a low remission rate with very few long term survivors when using standard treatment approaches. Azacytidine, a hypomethylating agent, has been shown to induce remission and prolong survival in patients with myelodysplastic syndromes; studying this approach to patients with AML is therefore warranted. We present results of an ongoing phase II trial treating elderly or frail AML patients with Azacytidine. Methods: AML elderly or frail patients, and therefore unfit for an intensive chemotherapy regimens, with a WHO performance status 3 were considered for this trial. Trial therapy consisted of 100mg/m2 of Azacytidine injected subcutaneously on 5 consecutive days every 28 days up to 6 cycles, stopping at 6 months if no hematological improvement achieved, or earlier in the case of progression or complications. Treatment was continued beyond 6 months in responding patients. Trial therapy was considered uninteresting if the response rate (CR + PR) within 6 months of therapy initiation was 15% or less and promising if 34% or more. Using the exact single-stage phase II design by A'Hern with a 5% significance level and 90% power, 43 patients were required: If 10 or fewer achieved a response within 6 months the trial therapy should not be considered for further investigation in its current format for this indication and patient population. Results: Between September 2008 and January 2010, 45 evaluable patients across 10 Swiss centers were accrued with a median follow-up of 7 months (range: 0 - 13). 27 (60%) were male, median age was 74 (range: 55 - 86) years and 35 (78.8%) had performance status 0-1. Patients had been excluded from more intensive chemotherapy regimens because of age (n = 37) or due to comorbidities or patient refusal (n=8). Five patients had therapy related AML. Patients received a median of 3 (range: 1 - 10) cycles. Treatment was stopped for not achieving a response by the 6th cycle in 2 patients and earlier in 26 patients (for disease progression in 5, toxicity in 3, patient refusal in 2, recurrent infections in 1, and death in 8). Seventeen patients remain on therapy. The median time spent in the hospital was 12 days (1 - 30) in 24/38 patients hospitalized during the first treatment cycle and 13 days (2 - 28) in 15/31 patients hospitalized during subsequent cycles. Adverse events of grade III or higher most frequently reported were constitutional or hematologic, i.e. fatigue in 5, febrile neutropenia in 8, infections in 6, dyspnea in 6, anemia in 3, neutropenia in 12 and thrombocytopenia in 10, hemorrhage in 2 and retinal detachment in 5. Based on available data on 38 patients, CR/CRi or hematologic improvement or stable disease within 6 months of trial registration was observed in a proportion of patients. Final and mature data, determining whether the predefined proportion of responding patients has been reached or not, will be presented at the conference. Up to now there were a total of 26 deaths. Median overall survival time was 5.7 months (95% CI: 3.1, 8.7). Conclusions: The current results of this slightly modified Azacytidine schedule demonstrate a feasible new therapy option for elderly or frail AML patients in an outpatient setting with moderate, mainly hematologic toxicity.

Implantació d'un sistema de gestió integrada: ISO 9001:00, ISO 14001:04 i OHSAS 18001:07, en un centre d'estètica i perruqueria

En aquests últims anys, són moltes les empreses que han optat per la utilització de sistemes de gestió normalitzats, per a garantir la rendibilitat i fiabilitat dels resultats de la implantació del sistema de gestió en qüestió. A la dècada dels 90 va ser quan la implantació de sistemes de gestió va començar a ser important en la majoria de sectors econòmics. L’evolució en els sistemes de gestió a trets generals va iniciar-se primerament en l’àmbit de la qualitat, seguidament en la gestió ambiental i en última instància en la prevenció de riscos laborals. Aquests tres tipus de sistemes de gestió, en els últims anys s’han anat integrant, de manera que s’han reduït els recursos i els esforços emprats en la gestió, millorant significativament l’eficàcia i l’eficiència d’aquests sistemes. L’objectiu principal que persegueix aquest projecte, és definir un sistema de gestió que permeti a l’empresa conduir les seves activitats de forma simplificada i ordenada, i que alhora faciliti la informació necessària per a corregir i millorar les activitats. Un altre objectiu que pretén aconseguir aquest projecte, és el de dissenyar un SGI que aprofiti les sinèrgies generades en els diferents àmbits de la pròpia empresa i fomenti les interaccions entre els diferents nivells de l’organització. En conseqüència, millorarà de forma important els fluxos d’informació dins de l’empresa minimitzant els esforços i la pèrdua d’informació. El mètode escollit per a la implantació del SGI, ha estat la Gestió per Processos, la qual es basa en la definició i seguiment dels processos de l’empresa, partint de les necessitats del client i acabant quan aquestes estan satisfetes. En conclusió, a la finalització del present projecte s’obtindrà un SGI, amb tots els processos de l’empresa definits i implantats, que doni compliment a les normes UNEEN-ISO 9001:00, UNE-EN-ISO 14001:04 i OHSAS 18001:07. Aquest SGI, que s’ha realitzat des d’un punt de vista documental i teòric, suposarà una millora de l’eficàcia operativa dels processos i una important millora competitiva de l’empresa.

Cetuximab In Combination With Docetaxel In Patients (Pts) With Metastatic Castration Resistant (Mcrpc) And Docetaxel-Refractory Prostate Cancer: Final Analysis Of The Multicenter Phase Ii Trial Sakk 08/07

There is no registered treatment (ttr) for pts with mCRPC who have progressive disease during or shortly after docetaxel (doc). EGFR overexpression increases in prostate cancer during the course of the disease. We investigated efficacy and safety of the combination of the monoclonal EGFR antibody cetuximab (cet) and doc in pts with mCRPC who are doc-refractory. Methods: Pts with mCRPC progressing during or < 90 days after at least 12 weeks of doc were included. Ttr consisted of the same doc regimen as prior to progression (35mg/m2 d1,8,15 q4w or 75mg/m2 q3w) in combination with cet (400mg/m2 d1, then 250mg/m2 weekly). Primary endpoint was progression free survival (PFS) at 12 weeks defined as absence of PSA progression or progression of metastases (mets). Secondary endpoints included toxicity, PFS at 24 weeks, PSA response, response of measureable disease and overall survival. 35 pts were needed in a Simon's two stage optimal design with a power of 90% and a significance level of 5% in order to test PFS rate at 12 weeks of £10% vs ?30%. Results: 35 evaluable pts were enrolled at 15 Swiss centers between 7/08 and 9/09. Median follow up was 14.8 months. Confirmed PFS at 12 weeks was 34% (95%CI 19-52%), PFS at 24 weeks was 20% and overall survival was 12.0 months (95%CI 7.1 -15.6). 20% (7/35) had a confirmed decline in PSA ? 50% and 31% (11/35) had a confirmed PSA decline ? 30%. Of pts with measurable disease (n=24) PR, SD and PD at week 12 was 4%, 54% and 25%, respectively (17% not evaluable). 3/9 (33%) pts with PDduring last doc ttr before inclusion reached the primary endpoint compared to 7/18 (39%) with PR or SD to last doc. 54% of evaluable pts experienced grade 3 and 6% grade 4 toxicity. Discussion: The result of the primary endpoint was promising in this first trial to test cet in combination with doc in pts with docetaxel-refractory mCRPC. Because this goal was achieved in such a highly pretreated pts population it appears that inhibition of the EGFR pathway may play a more important and persistent role in the treatment of prostate cancer than perceived so far. Further research is therefore warranted. Disclosure: R. Cathomas: - Membership on advisory board for sanofi aventis (suisse) and Merck. S. Gillessen: - Membership in advisory board for Sanofi Aventis. All other authors have declared no conflicts of interest.

Enquesta sobre l’ús i la satisfacció de les biblioteques de la UPC per part dels estudiants : curs 2006/07

Per tal de valorar el grau de satisfacció que tenen els estudiants de les biblioteques de la UPC, el Servei de Biblioteques i Documentació elabora amb periodicitat biennal“L’enquesta sobre l’ús i la satisfacció de les biblioteques per part dels estudiants”. La primera enquesta es va realitzar el curs 1994-95, així doncs, els resultats que es presenten en aquest document corresponen a la setena edició.Aquesta enquesta té com a objectiu principal obtenir informació sobre la percepció quetenen de les biblioteques de la UPC els usuaris que les visiten i conèixer així l’ús i el grau de satisfacció dels serveis, les instal·lacions i els recursos bibliogràfics.A partir de l’anàlisi de les dades obtingudes, les biblioteques estableixen propostes que han de comportar una millora dels serveis i les instal·lacions de les biblioteques.

Modelling Bone Mineral Density in Swiss Breast Cancer Patients Treated with Letrozole, Tamoxifen and Sequences of Letrozole and Tamoxifen in the BIG 1-98 Study (SAKK 21/07).

Background: Bone health is a concern when treating early stage breast cancer patients with adjuvant aromatase inhibitors. Early detection of patients (pts) at risk of osteoporosis and fractures may be helpful for starting preventive therapies and selecting the most appropriate endocrine therapy schedule. We present statistical models describing the evolution of lumbar and hip bone mineral density (BMD) in pts treated with tamoxifen (T), letrozole (L) and sequences of T and L. Methods: Available dual-energy x-ray absorptiometry exams (DXA) of pts treated in trial BIG 1-98 were retrospectively collected from Swiss centers. Treatment arms: A) T for 5 years, B) L for 5 years, C) 2 years of T followed by 3 years of L and, D) 2 years of L followed by 3 years of T. Pts without DXA were used as a control for detecting selection biases. Patients randomized to arm A were subsequently allowed an unplanned switch from T to L. Allowing for variations between DXA machines and centres, two repeated measures models, using a covariance structure that allow for different times between DXA, were used to estimate changes in hip and lumbar BMD (g/cm2) from trial randomization. Prospectively defined covariates, considered as fixed effects in the multivariable models in an intention to treat analysis, at the time of trial randomization were: age, height, weight, hysterectomy, race, known osteoporosis, tobacco use, prior bone fracture, prior hormone replacement therapy (HRT), bisphosphonate use and previous neo-/adjuvant chemotherapy (ChT). Similarly, the T-scores for lumbar and hip BMD measurements were modeled using a per-protocol approach (allowing for treatment switch in arm A), specifically studying the effect of each therapy upon T-score percentage. Results: A total of 247 out of 546 pts had between 1 and 5 DXA; a total of 576 DXA were collected. Number of DXA measurements per arm were; arm A 133, B 137, C 141 and D 135. The median follow-up time was 5.8 years. Significant factors positively correlated with lumbar and hip BMD in the multivariate analysis were weight, previous HRT use, neo-/adjuvant ChT, hysterectomy and height. Significant negatively correlated factors in the models were osteoporosis, treatment arm (B/C/D vs. A), time since endocrine therapy start, age and smoking (current vs. never).Modeling the T-score percentage, differences from T to L were -4.199% (p = 0.036) and -4.907% (p = 0.025) for the hip and lumbar measurements respectively, before any treatment switch occurred. Conclusions: Our statistical models describe the lumbar and hip BMD evolution for pts treated with L and/or T. The results of both localisations confirm that, contrary to expectation, the sequential schedules do not seem less detrimental for the BMD than L monotherapy. The estimated difference in BMD T-score percent is at least 4% from T to L.